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Summary 
The serine protease HTRA1 has previously been identified as playing a role in the 
degradation of extracellular matrix (ECM) proteins, thus implicating it in various 
degenerative disorders such as intervertebral disc degeneration, arthritis and age-
related macular degeneration (AMD). However, findings from previous studies 
performed in our laboratory investigating the role of HTRA1 in the regulation of 
mesenchymal stem cells (MSCs) osteogenesis, have led us to re-evaluate its 
biological properties with respect to mammalian tissue development and disease. 
In the current study, we asked whether HTRA1, in addition to its positive effects on 
MSC osteogenesis, could also influence the adipogenic differentiation of MSCs. In 
order to address this question, we investigated the effects of exogenously added 
recombinant HTRA1 and small interfering RNA (siRNA)-mediated depletion of 
HTRA1 on the development of hMSCs into mature adipocytes. The effects of 
HTRA1 were assessed using different techniques including qRT-PCR, intracellular 
and extracellular protein analyses, enzyme assays and histological analyses. We 
could demonstrate that HTRA1 acts to significantly suppress adipocyte 
development, primarily through upregulation of JNK activity and MMP production. 
Moreover, we were able to localize HTRA1 to sites of immune cell infiltrate within 
the adipose tissue of an insulin resistant obese patient, thus implicating it in 
adipose tissue remodeling under pathological conditions. In conclusion, our 
findings identify HTRA1 as a negative regulator of hMSC adipogenesis, which may 
be of relevance when considering its potential role in the underlying processes 
governing adipose tissue and adipocyte dysregulation. Moreover, the differential 
effects imparted by HTRA1 on hMSC adipogenic and osteogenic differentiation 
may also offer novel insights into its potential impact on other pathological 
conditions such as age-related bone loss, where its capacity to inhibit 
adipogenesis and stimulate osteogenesis would be deemed beneficial to the 
preservation of bone quality. 
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Zusammenfassung 
Die Serinprotease HTRA1 wurde als ein Faktor beim Abbau extrazellulärer Matrix 
(ECM) Proteine identifiziert, wodurch sich Implikationen in verschiedenen 
degenerativen Erkrankungen wie Bandscheibenschäden, Arthritis und 
altersbedingte Makuladegeneration (AMD) ergeben. Jedoch zeigten Ergebnisse 
früherer Studien unseres Labors welche Rolle HTRA1 in der Regulation der 
Osteogenese mesenchymaler Stammzellen (MSCs) hat, was uns zu einer 
Neubewertung seiner biologischen Eigenschaften im Hinblick auf humane 
Gewebeentwicklung und Krankheiten führte. In der aktuellen Studie fragten wir, ob 
HTRA1, zusätzlich zu seiner positiven Auswirkungen auf die Knochenbildung in 
MSCs, auch die adipogene Differenzierung von MSCs beeinflussen könnte. Um 
diese Frage zu beantworten, untersuchten wir die Auswirkungen exogen 
zugegebenen rekombinanten HTRA1 Proteins, sowie die von small-interfering 
RNA (siRNA) vermittelte Depletion von HTRA1, hinsichtlich ihrer Auswirkungen 
auf die Entwicklung von hMSCs hin zu reifen Adipozyten. Diese Auswirkungen von 
HTRA1 wurden mittels verschiedener Techniken einschließlich qRT-PCR, intra- 
und extrazellulärer Proteinanalysen, Enzymassays und histologischer Analysen 
bewertet. Wir konnten zeigen, dass HTRA1 die Adipozytenentwicklung deutlich 
unterdrücken kann, in erster Linie durch das Heraufregulieren von JNK-Aktivität 
und MMP-Produktion. Darüber hinaus konnten wir HTRA1 im Bereich von 
Immunzellen, die das Fettgewebe eines insulinresistenten adipösen Patienten 
infiltrieren, lokalisieren, was eine Beteiligung am Umbau des Fettgewebes unter 
pathologischen Bedingungen nahe legt. Abschließend konnten unsere 
Erkenntnisse HTRA1 als negativen Regulator der hMSC Adipogenese 
identifizieren, was, angesichts einer möglichen Beteiligung in den zugrunde 
liegenden Vorgängen während Fettgewebe- und Fettzellfehlregulation, von großer 
Bedeutung sein kann. Darüber hinaus können die gegenteiligen Wirkungen von 
HTRA1 auf hMSC Adipogenese und Osteogenese auch neue Erkenntnisse über 
mögliche Auswirkungen auf andere pathologische Zuständen liefern, wie z.B. 
altersbedingten Knochenverlust, wo die Fähigkeit Adipogenese zu hemmen und 
Knochenbildung zu stimulieren, als vorteilhaft interpretiert würde, um so dem 
Prozess der Erhaltung der Knochenqualität positiv beizusteuern.  
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Abbreviations 
ADAM     a disintegrin and metalloproteinase 
AMD     age-related macular degeneration 
AMPK     AMP-activated protein kinase 
ASC     adipose-derived stromal cell 
ATP     adenosine triphosphate 
BAT     brown adipose tissue 
BMSC     bone marrow stromal cell 
CVD     cardiovascular disease 
ECM     extracellular matrix 
ESC     embryonic stem cell 
FFA     free fatty acid 
FS     follistatin 
GAG     glucosaminoglycan 
HSC     hematopoietic stem cell 
HTRA1    high temperature requirement factor A1 
IFN     interferon 
IGF     insulin-like growth factor 
IL     interleukin 
iPS     induced pluripotent stem cell 
MMP     matrix metalloproteinase 
MSC     multipotent stromal cell 
OA     osteoarthritis 
Ppar     peroxisome proliferator-activated receptor 
RANK     receptor activator of nuclear factor- κ B 
RANKL    receptor activator of nuclear factor- κ B ligand 
SVF     stromal vascular fraction 
TGF     transforming growth factor 
TNF     tumor necrosis factor 
WAT     white adipose tissue 
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1 Introduction 
1.1 Stem cells 
It is well acknowledged that the main underlying prerequisite of a cell to be 
classified as a stem cell lies within its capability to either differentiate into one of 
multiple lineages of a more specialized cell type or to replicate and divide and to 
reside in a quiescent state [1-3]. The ability to give rise to and to fulfil any known 
function in a multicellular organism gives the stem cell a central role in maintaining 
a healthy homeostasis and balance, and is very likely to be one of the key features 
of general health and survival of an individual [4-6]. 
1.1.1 Stem cell niche 
When trying to characterize a stem cell and its fate and properties, of great 
importance is the environment that it is exposed to. The stem cell niche describes 
all extrinsic factors and stimuli that interact with the stem cell to determine its 
cellular fate [7, 8]. The list of contributing factors is long and spreads from 
hormones, growth factors and other protein based compounds to proteoglycans, 
sugars and even inorganic factors such as pH, and extracellular matrix (ECM) 
architecture. All of these stimuli are generally sensed by a variety of intracellular 
second messenger pathways of the cell and ultimately lead to a rearrangement of 
the transcriptome and hence can create an entirely different type of cell. The 
complexity of the process of stimulation between a stem cell and its niche cannot 
be underestimated, as the number of potential levels to manipulate this interaction 
is extremely high [9]. Scientists therefore not only focus on hormonal growth factor 
stimulation of the stem cell, but an increasing number of laboratories around the 
world are now extensively studying the mere influence of the physical surrounding 
and environment of the cell (e.g. ECM composition), as this seems to have a direct 
influence on cells [10]. Indeed, via protein-protein interactions directly crossing the 
cell membrane barrier, the cell has found an additional way to control the dialogue 
with its niche [11-14]. Thus, an entirely new way of communication between the 
cell and its exterior is thereby created, which is closely linked to the cell´s 
cytoskeleton [14]. Together, all factors contribute to the specific characteristics of 
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what we call the stem cell niche. 
1.1.2 Stem cell hierarchy 
Not every stem cell is the same. In fact, a huge variety of stem cells was identified 
and new types are added to the list every year [9]. Different types of stem cells are 
classified based on their capacity to differentiate into specific cell types: 
 
1. Totipotency: This status refers to cells that are able to differentiate into 
practically any known cell of the body, including all cells of the Endo-, 
Meso- and Ectoderm. These cells are therefore able to give rise to an entire 
organism. So far, the only known totipotent cell type is the zygote, although 
first breakthroughs in induced totipotent cells were made rather recently 
[15]. 
2. Pluripotency: The pluripotent status of a stem cell is reached when it is 
capable of differentiating into all cell types of the germ layers. However, the 
difference to totipotency lies mainly in the fact that a pluripotent cell is not 
self-sufficient and cannot give rise to an individual organism. The cell types 
that are classified as pluripotent are therefore embryonic stem cells (ESCs), 
as well as induced pluripotent stem cells (iPS) [16]. 
3. Multipotency: The term multipotency describes stem cells with the ability to 
generate cells from one germ layer. Different types of cells are known to be 
typically involved in the differentiation of the mesoderm, such as 
hematopoietic and bone marrow derived stem cells. The great variety, easy 
accessibility and utility, make the mesenchymal stem cell an interesting 
target for regenerative medicine, without the compromising ethical aspects 
found when dealing with ESCs [17]. 
4. Oligopotency: This newly established term defines stem cells that are 
already predetermined for a specific cell type, such as osteoblasts or 
preadipocytes and exhibit a very limited capacity to differentiate into other 
cell types [18]. 
5. Nulipotency: Nulipotency describes a cell that is terminally differentiated 
and exhibits no more differentiation potential [1]. 
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Figure 1: Schematic overview of the hematopoietic and mesenchymal stem 
cell differentiation. (© Terese Winslow 2008) 
 
1.1.3 Differentiation 
Stem cell differentiation is the process of an unspecified cell type converting 
towards a more specified cell until it is classified as a somatic, hence terminally 
differentiated cell. It is a complex, tightly regulated and orchestrated process which 
is in the focus of cell biology research for decades. Differentiation affects every 
aspect of the cell including the transcriptome and proteome, as well as cell 
morphology, cytoskeleton composition, cell membrane architecture, secretome, 
ECM composition, metabolic state and activity, microRNAs, epigenetics 
(hypermethylation), histone modifications etc. The interaction of the stem cell with 
its niche and vice versa is therefore likely to be one of the most complex single cell 
occurrences that we know [8, 19].  
In general, global changes in the gene expression of the cell are the underlying 
force that is driving cellular differentiation [20-22]. However, the one rule that holds 
true for all types of differentiation for every cell type is that it is a one way route. 
Once a cell is terminally differentiated, the changes made are absolute and the cell 
will always remain in this state. There are exceptions to that rule 
(transdifferentiation, iPS), but they remain a rare exception [16, 23].  
As a stem cell can either divide and thereby multiply, or start the process of 
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differentiation, two types of cell division are commonly described for a stem cell: 
 
1. Symmetric cell division describes the process of a stem cell that divides 
and gives rise to two cells with an identical cellular fate. It is found during 
growth or regeneration. 
2. Asymmetric cell division is the process where two daughter cells have a 
different cellular fate. While one of the two daughter cells remains identical 
to the parental generation, the other cell starts differentiation and thus, 
loses its stem cell characteristics [24]. 
 
Understanding the details of stem cell differentiation is clearly one of the major 
scientific challenges of our times, as it, as mentioned, comprises almost every 
aspect of cellular biology in a highly organized and orchestrated way and therefore 
holds many answers to diseases such as cancer, autoimmune disorders and other 
cell-based diseases [2, 6]. 
1.1.4 Adult vs. embryonic stem cells 
As highlighted in the previous sections, stem cells possess the potential to play a 
major role in fighting diseases. While a cell that exhibits maximum differentiation 
capabilities (ESCs) is potentially of most use for basic research, this cell type 
clearly also exhibits the most controversially discussed ethical issues [4, 9], as the 
cells have to be extracted from a zygote or early embryo [15]. Especially when it 
comes to scenarios of human medical applications, this hurdle is likely to become 
unassailable. Therefore, adult stem cells that in fact do not show a totipotent 
differentiation potential but show pluripotent features appear to be the saviour in 
this debate. Adult stem cells remain in the body throughout an organism’s lifetime. 
In fact, their permanent influence on maintenance and homeostasis of the 
organism appears to become more and more apparent [5, 6]. Furthermore, 
research is trying to put their regenerative potential to good use, as these cells can 
be extracted from the body and manipulated in vitro for further applications [2]. 
The following section lists some examples of the different adult stem cell sources 
and their implications in human medicine: 
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1. Hematopoietic stem cells derived from the mesoderm are located in the 
red bone marrow and give rise to all types of blood cells. Specifically, they 
give rise to myeloid (e.g. erythrocytes, thrombocytes, monocytes and 
macrophages) and lymphoid (e.g. NKCs and lymphocytes) cell types. 
Among many other research implications, these cells are broadly used for 
stem cell transplantation of the red bone marrow which helps to fight 
leukaemia. It therefore represents a well-established field of application for 
human stem cells [25, 26]. 
2. Mammary stem cells are a source for the cells of the mammary gland and 
are known to be involved in the carcinogenesis of the breast [27]. These 
cells have been successfully proven to be multipotent or even totipotent and 
are thus an interesting candidate to conduct research with in the future [28]. 
3. Intestinal stem cells are found in the epithelium of the intestines. They 
provide a source for the continuously regenerating epithelium of the 
intestines. Due to their lifelong commitment to cell division, they also 
represent an important contributor to the carcinogenesis of the intestinal 
tissue [29]. Their potential implications for research and medicine are also 
in the focus of regenerative research today [30]. 
4. Mesenchymal stem cells (MSCs) belong to the most studied cell type of 
adult stem cells. They are of a stromal origin and are therefore found in 
many tissues of the body. Known sources of stromal cells include the bone 
marrow, the placenta, adipose tissue, blood, the lung, the umbilical cord 
and teeth. This makes them especially interesting, as they can differentiate 
into a large variety of cell types including osteoblasts, chondrocytes and 
adipocytes [7].  
 
As this Thesis is primarily concerned with the adipogenic potential of human MSCs 
(hMSCs), the following sections are dedicated to providing a more detailed 
description of hMSC adipogenesis and the major events governing this process.  
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1.2 hMSC adipogenesis 
Adipogenesis describes the process of adipocyte formation. It usually involves the 
differentiation from a pre-adipogenic cell type towards the terminally differentiated 
adipocyte, which is capable to fulfil all functions characteristic for adipose tissue as 
a whole. 
The main biological function of adipocytes and thereby fat tissue in general, is to 
store large quantities of energy. This energy (stored as triglycerides) is readily 
available for the cells in the surrounding environment and even cells at distant 
locations. Furthermore, hormone secretion gives it endocrine-like features (c.f. 
section 1.2.3). Next to its energy storage function, fat tissue is also used for 
insulation and protection of the body [31]. In the following sections, the adipose 
tissue with its cells and functions will be explained in detail. 
1.2.1 Adipose tissue 
Adipose tissue is a connective tissue mainly composed of adipocytes that store 
lipids in enormous amounts. Due to the hydrophobic properties of lipid, the energy 
that is kept in the form of fatty acids needs to be stored differently than that from 
for example ATP or NADPH, which is simply kept in solution within specialized 
compartments of the cell.  
The adipocytes derive from adipocyte precursor cells, i.e. from the hMSC pool of 
the adipose tissue. They exhibit a specialized metabolism which enables efficient 
storage and release of this energy source, which is further highlighted in section 
1.2.1.1. Adipocytes undergo a constant turnover of uptake and release of lipids 
(shuttled in the form of free fatty acids (FFAs)) and, depending on whether or not 
the uptake of lipid exceeds the release, the cells either expand in size 
(accumulation of lipids) or enter the so called mobilization phase (lipid release) 
[32]. 
Free fatty acids are the only fat molecule available for uptake for these cells. Since 
fatty acids taken up by ingestion only occur in the form of lipoproteins, it is 
necessary to break down these solubilized lipoproteins into free fatty acids to 
make them readily available for the cells. A protein called lipoprotein lipase (LPL), 
which is found in the ECM of adipocytes, is the limiting factor that makes this 
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conversion possible. Once the FFA has entered the adipocyte, it is reassembled 
into triglycerides and is finally stored in lipid droplets that build hydrophobic 
spheres in the cytoplasm of the cell. These spheres, called lipid droplets, can 
make up a huge percentage of the total volume of the cell [33]. 
The regulation of uptake and release of these FFAs and lipids is realized mostly by 
insulin. Stimulation of adipocytes by insulin results in an increased uptake of FFAs 
and thereby in the expansion of the adipocyte. On the other hand, hormones such 
as epinephrine, glucagon and the adrenocorticotropic hormone (ACTH) regulate 
lipolysis and thereby the release of FFAs from the cell [34]. 
Next to the adipocytes, the adipose tissue also contains a fraction (although only 
to a small percentage) of different cell types, summarized as stromal vascular 
fraction (SVF). This synonym is a broad term for all other cell types found in the 
adipose tissue which includes hMSCs, preadipocytes, endothelial progenitor cells, 
macrophages, as well as immune cells like B- and T-cells. This pool of non-lipid 
carrying cells plays an important role in the maintenance of the tissue by providing 
a source for new adipocytes, amplification for signals from other tissues as well as 
immunological regulation of the adipose tissue. The exact role of these cells within 
the adipose tissue is poorly understood, but is likely to go beyond being a mere 
backup for the adipocyte cell pool and towards a direct involvement in tissue 
health maintenance (c.f. chapter 1.1) [33, 35]. As an example, macrophages are 
known to be involved in the maintenance of the adipose tissue of obese 
individuals. The percentage of macrophages within the white adipose tissue can 
go up to 50%, as they help to catabolize dead adipocytes (usually due to a locally 
occurring inflammation reaction), surround them and form crown-like structures 
(CLS). Hence, they are directly involved in the depletion of defective adipocytes 
[36, 37] and thereby fat tissue maintenance. 
 Energy metabolism of fatty acids 1.2.1.1
As mentioned earlier, adipose tissue has enabled a way for the organism to make 
the energy stored in fatty acids readily available. To do so, a unique metabolic 
pathway is found in the adipocytes, which will be described in detail in this chapter. 
A fat molecule consists of three fatty acid chains which are connected via a 
glycerol backbone. Hence, a fatty acid simply is a long chain of carbon and 
hydrogen atoms with a lot of energy stored in the bonds [38]. 
Introduction 
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Starting from the dietary ingestion of fatty acids as triglycerides, the fat is broken 
down in the intestines by the pancreatic lipase into monoglycerides and free fatty 
acids. After they are solubilized into micelles together with bile salts and certain 
proteins, the lipids can now be absorbed into the intestine epithelium by 
specialized membrane proteins. The triglycerides (in the form of chylomicrons and 
lipoproteins) are now rebuilt in the cells of the intestine and can enter the blood 
stream and thereby the circulation of the body. Three types of cells can take up 
the lipids to make use of their stored energy: hepatocytes (liver), myocytes 
(muscle) and adipocytes (fat tissue). While the liver cells are mainly involved in the 
processing of fat into other types of lipoproteins, such as very low density 
lipoprotein (VLDL) and low density lipoprotein (LDL) in order to make them usable 
elsewhere, muscle cells make a direct use of the energy of the fatty acids and the 
adipocytes are responsible for their storage and release. However, the detailed 
processes underlying the fatty acid metabolism of the hepatocytes and muscle 
cells will not be further discussed here, but instead the process of uptake and 
release of fatty acids by adipocytes will be in the focus. 
Once lipoproteins have become bound to the extracellular portion of the 
adipocyte´s cell membrane (i.e. the ECM), the enzyme lipoprotein lipase (LPL) 
breaks them down into FFAs to enable their directed uptake into the cell by 
specific membrane proteins (e.g. LRP-1) [39]. In the cytoplasm of the adipocyte, 
these neutral fatty acids now form lipid droplets, consisting of a phospholipid layer 
with a core of triacylglycerols and sterol esters. A covering layer of a protein called 
perilipin prevents endogenous degradation by lipases. These lipid droplets can 
merge into bigger lipid droplets, if necessary, and can make up to 90% of the cell 
size [40]. 
When needed (for instance upon low insulin levels due to low blood sugar levels) 
the adipocyte can release large quantities of fatty acids into the circulation. An 
extracellular stimulus provokes an intracellular secondary messenger cascade 
which results in an activation of the hormone-sensitive lipase (HSL). The HSL 
breaks down the triglycerides of the lipid droplets into glycerol and free fatty acids. 
The process of fatty acid release into the blood is called lipolysis. Contrary to the 
fatty acids bound to lipoproteins, these FFAs in the blood (bound to serum albumin 
to facilitate solubility) remain as FFAs which makes them easily accessible for 
target tissue that is in need of energy. The FFAs are now metabolically available 
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for muscle and cardiac tissue, whereas the glycerol is taken up by the liver for 
gluconeogenesis for the generation of glucose which is the only energy source for 
brain tissue. 
Interestingly, of all the molecules, fatty acids yield the most adenosine 
triphosphate (ATP) (energy per gram ratio), which represents the main source of 
energy for cells. When the cell is in need of energy, the FFA gets broken down into 
Acetyl CoA by an enzyme called acetyl Coenzyme-A. The resulting Acetyl CoA 
molecules are then oxidized in the citric acid cycle, just like glucose in the aerobic 
glucose metabolism. However, for every two carbon atoms in a fatty acid, 17 ATP 
molecules can be generated, making fatty acid a highly energetic molecule [38, 
40]. To further clarify the connection between fatty acid and glucose metabolism in 
the human body, a simplified overview of these two pathways can be found in 
figure 2. 
 
 
           
Figure 2: Schematic representation of the glucose and fatty acid catabolism 
[41] REMARK: please note that Glucose Oxidation as depicted in this figure 
is inaccurate and requires correction. 
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 Brown vs. white adipose tissue 1.2.1.2
It is of great importance to differentiate between white and brown fat tissue (WAT 
and BAT) when characterizing adipose tissue. While the cells of the WAT derive 
from hMSCs and carry one large lipid droplet in the cytoplasm in their mature 
state, cells from the BAT appear to be deriving from muscle progenitor cells (they 
share surface markers such as Myf5, which cells from the WAT are lacking) and 
numerous, smaller lipid droplets can be found in these cells [42]. 
The main difference in function is that WAT cells store excessive lipids collected 
from the periphery of the body and make them available for the whole organism, 
while brown adipose cells are mainly responsible for body heat generation. This 
heat production is realized by a large number of mitochondria that are found in the 
cytoplasm of the BAT, which gives them their brownish appearance (c.f. figure 3). 
Next to producing ATP, mitochondria can also make use of the proton gradient in 
a different way. Instead of using the gradient for enzymatic ATP synthesis, the 
protons flow back into the cytoplasm via uncoupling protein 1 or thermogenin. This 
protein allows usage of the energy stored in the proton gradient to be released as 
heat [43]. 
Large quantities of BAT are therefore mostly found in new-borns and hibernating 
animals that produce body heat not by an unconscious hyperactivity of muscles 
(shivering under hypothermal conditions), but by the help of the BAT. Importantly, 
the high mitochondrial activity of BAT consumes a lot of oxygen, which is why BAT 
is highly vascularized compared to the WAT [44]. 
Overall, in adult humans BAT is only found in small quantities. However, as it was 
believed that this adipose tissue is exclusively found in infants and other animal 
species, it is important to note that BAT remains active throughout life and shares 
higher similarities to muscle tissue than to WAT. Therefore, BAT may have other 
as yet unknown implications. On the other hand, WAT usually makes up to 20% of 
the body weight of men and women and is directly involved in energy metabolism 
of the body and indirectly in body heat maintenance by insulating the body [45]. 
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Figure 3: Light microscopy image of a histological staining of brown and 
white adipose tissue. (© Charmaine S. Tam et al) 
 
1.2.2 Adipose tissue function 
The main functions of adipose tissue can be summarized as follows: 
 
1. Thermal insulation of the body (WAT) 
2. Energy storage and release (WAT) 
3. Storage of excessive fats, that would otherwise be harmful for the organism 
(WAT) 
4. Body heat production (BAT) 
 
However, next to its classical functions directly implicated to fat storage and 
release as well as thermal insulation, the fat tissue may hold other regulatory 
functions with implications for the whole organism. The discovery of so called 
adipokines gives us a hint as to the importance of the mutual dialogue of different 
compartments of the human body. Thus, the importance of an intact adipose 
tissue may even go beyond the diseases indirectly or directly linked to the adipose 
tissue (c.f. section 1.2.4) and may become of great importance in the future of 
medicine. 
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1.2.3 Adipokines 
It was originally believed that cytokines, hormones and other immunologically 
active molecules are exclusively secreted by immune cells such as B- and T-
lymphocytes, macrophages etc. It is now being appreciated that the number of 
cells secreting and sensing cytokines is much larger, including myocytes, 
adipocytes, fibroblasts and many more [46]. 
Since adipose tissue is closely linked to many metabolic events in the human 
body, it is becoming increasingly apparent that a large number of so called 
adipocytokines or adipokines are secreted and also sensed by adipocytes 
themselves. Understanding the crosstalk of adipose tissue and other endocrine 
organs (pancreas, liver, bone etc.) is a major task of basic research in order to 
understand a variety of human diseases such as obesity, type 2 diabetes, and 
even osteoporosis etc. [47, 48]. 
One of the first adipokines to be discovered was leptin, but many others have 
followed since. This also includes factors not exclusive to adipose tissue, but 
which are also released by other cell types. This includes interleukins and 
interferons (IL-6, RBP-4, TNF-α, IFN-γ etc.). A second prominent adipokine is 
adiponectin, which is known to be involved in many cellular and endocrine 
regulatory processes. Together, leptin and adiponectin regulate the activity of 
AMP-activated protein kinase (AMPK), which is known to be a major regulator of 
apoptosis, differentiation and the cell cycle. This highlights the central role of 
adipose tissue to regulate globular parameters in the human body, which can 
simply have an impact on appetite and glucose levels (insulin regulation), or can 
even extend to the regulation of stem cell differentiation [49, 50]. Their involvement 
in adipose tissue regulation and even disease progression has been under 
investigation by researchers for years and holds great potential for therapeutic 
applications [51]. 
Conclusively, due to the existence of adipokines, it is likely that the immunology of 
the human body extends beyond the classical immune cell types, such as 
lymphocytes, T-cells and macrophages, and may involve many more cell types. 
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1.2.4 Adipose tissue associated diseases 
One of the major health risk factors of our generation is obesity. This disease, 
closely associated to the adipose tissue, is directly linked to the most common 
cause of death worldwide, which are cardiovascular diseases (CVDs). While 
obesity itself is not a life threatening condition, many diseases result from obesity, 
such as the before mentioned CVDs, as well as type 2 diabetes, cancer and 
osteoarthritis (OA) [47, 52]. It is generally caused by a combination of one of three 
factors: 
 
a) Excessive food intake 
b) Insufficient physical activity 
c) Genetic predisposition 
 
Although exceptions have been described, there is no trustworthy evidence 
convincing enough to show any other factor to be involved in the progression of 
obesity [53]. The medical classification of obesity nowadays refers to the body 
mass index (BMI) which was introduced by the world health organization (WHO) 
[54]. An overview about the indices can be found in figure 4. Many secondary 
effects on the organism are known to be caused by obesity. An overview about the 
most well-known relationships is given in the following: 
1) CVDs are the most common, occurring as a direct result of chronic obesity. 
Many factors are involved in the development, including dyslipidemia (a 
massive increase of lipids or lipoproteins in the blood), high blood pressure, 
thrombosis, embolisms, etc. An increase in blood lipids contributes to 
plaque formation on blood vessel epithelia and thereby induces stenosis of 
the blood vessels. This facilitates the occurrence of ischemia, hence heart 
diseases such as myocardial infarctions, as well as strokes, thrombi, 
embolisms etc. A high blood pressure further increases the risk of 
cardiovascular malfunctions. Taken together, many reactions resulting from 
CVDs can be life threatening, which is why CVDs are a major reoccurring 
problem in most developed countries [55].  
2) Type 2 diabetes is the result of insulin resistance and/ or insufficient insulin 
production from the beta cells of the pancreas. Insulin resistance describes 
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the inability of the muscle, the liver and the fat tissue to respond to insulin. 
In a healthy organism insulin reduces the amount of glucose being released 
from the liver in order not to increase blood sugar levels further. However, 
due to insulin resistance, the release of sugar into the blood remains at a 
high level and at the same time, relative to these high amounts of blood 
sugar, insulin levels remain low. The combination of high blood sugar levels 
and low insulin levels results in a very low uptake of glucose by adipose 
tissue and muscle cells. Also, the level of lipolysis from adipose tissue may 
be increased, further elevating the levels of energy molecules into the 
blood, as insulin normally provokes the storage of FFA´s rather than their 
release [56]. Thus, next to the resulting effect that the excess glucose in the 
blood is not available for target cells, high amounts of glucose in the blood 
can even be toxic, which can have drastic consequences over longer time 
periods [57]. 
 
 
 
Figure 4: graphical representation of the BMI score. (© www.metric.org.uk) 
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1.3 The ECM as a regulator of hMSC multipotency 
The ECM is a general term describing all extracellular molecules that are secreted 
from a cell and fulfil their function only in the extracellular space. Typically, the 
ECM was thought to exhibit structural and biochemical support only, but it is now 
becoming increasingly apparent, that the ECM is more than just filling up the 
extracellular space or building up connective tissue such as bone or cartilage. It is, 
in fact, also involved in many regulatory processes in the crosstalk between cells 
and tissues [11, 58, 59]. The importance of remodeling the ECM is now being 
appreciated as one of the major events in stem cell differentiation, tissue 
development and regeneration, and even cancer progression [14, 58, 60, 61]. 
The following chapter will therefore explain the ECM´s structure, function, key 
players and involvement in biological processes and disease development. 
1.3.1 General set up 
Although very different between different cell types, a general architecture of the 
ECM can be described for all types of cells. Two types of an ECM can be 
distinguished: 
 
1. While the basement membrane serves as a barrier between any given 
epithelium, mesothelium and endothelium found in the body to its 
underlying tissue, the  
2. interstitial space makes up all other extracellular space that is found 
throughout the body. 
 
The name basement membrane is therefore misleading as it is an extracellular 
space, but with the specific function to separate two distinct tissue compartments 
from one another. The main components of every ECM usually comprises 
proteoglycans and other non-proteoglycan polysaccharides and a large number of 
different fibers. Proteoglycans mainly consist of heparan-, chondroitin- and 
keratin-sulfate. These are three different types of carbohydrate polymers of the 
ECM that are bound to proteins such as perlecan, agrin and collagens, but also 
proteins bound directly to the cell membrane. They are usually referred to as 
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GAGs (glucosaminoglycans), which is the same molecule without a specific 
protein attached to it [12]. Together they form a branched, tightly interconnected 
net of proteoglycans that, due to their net negative charge, attracts positively 
charged ions and thereby water, making it a well-hydrated environment. This 
guarantees a lively exchange between the cell and its surrounding environment. 
Furthermore, this network builds a scaffold for many regulatory molecules (like 
growth factors, hormones and other peptides) to bind to and even be stored in 
[62]. As many of the peptides associated to the carbohydrate are directly or 
indirectly linked to membrane proteins of the cell, these cell-cell or cell-matrix 
interactions can have a direct intracellular signaling event via membrane-spanning 
proteins like integrins or other cell surface receptors. Furthermore, the close 
proximity of this part of the ECM makes many substrates available for an 
interaction of compounds secreted by the cell (e.g. lipoprotein lipase in fatty acid 
uptake or alkaline phosphatase in matrix mineralization during osteogenesis) [63, 
64]. 
Non-proteoglycan polysaccharides (mainly represented by hyaluronic acid) are 
not bound to any protein of the ECM or the membrane of the cell. Their specific 
function is to provide mechanical shock absorbance by exhibiting swelling 
properties of the ECM with relatively large amounts of water. They are therefore 
mostly found in load-bearing joints, but also make up a key component of the 
interstitial space. However, studies do provide evidence for hyaluronic acid directly 
associating with CD44, to which it exhibits regulatory functions. Thus, its 
implications in many processes of the body may be possible [65, 66]. 
The group referred to as fibers are the most abundant proteins found in the ECM. 
Collagen is by far largest member of this family and is found in large quantities in 
every ECM of any cell type. This makes it the most abundant protein of the human 
body, as it is the main protein component in many tissues such as bone tissue, 
skin, cartilage, ligaments, tendon and blood vessels. Collagen’s main function is to 
give stability to a connective tissue due to its remarkable tensile strength, realized 
by its mostly fibrous nature [67]. It is generally accepted that 80 – 90% of 
collagens in the human body are formed by Collagen I – III [68]. Due to the fact 
that collagens are secreted from the cells in a premature state (procollagen), 
collagenases on the outside of the cell are responsible for the maturation of the 
ECM by cleaving the procollagen molecules. A malfunction in the respective 
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collagen gene or its specific collagenase enzyme results in a number of diseases 
affecting connective tissues, such as osteogenesis imperfecta [69], epidermolysis 
bullosa etc. [70]. In order to allow for tensile strength and also three-dimensional 
elasticity within the tissue, a protein called elastin is also found in large quantities 
in tissues that require elasticity more than stiffness. Examples are the skin, blood 
vessels as well as the lungs. The elastin provides stretching properties of the 
tissue and is mainly secreted by fibroblasts and cells of the smooth muscle tissue, 
but typically found in any ECM. Since elastin is encoded by a single gene, 
deficiencies in elastin synthesis also result in diseases of the connective tissue 
such as cutis laxa or Williams syndrome which make the skin hyper flexible [71]. 
In addition to proteoglycans, other peptides associated to sugar residues can be 
found in the ECM. Fibronectin is a glycoprotein important for the linkage of the 
ECM to collagen, thereby anchoring the cell closer to its ECM. It is believed that 
this allows the cell to execute a certain degree of movement within the ECM by 
reorganizing the intracellular cytoskeleton [72]. Thus, fibronectin is an essential 
molecule for cell-ECM contact which allows the cell to sense the status of its ECM, 
thus making it a vital part of the cell-ECM dialogue. Furthermore, proteins called 
laminins are complex molecules that are also found in the ECM, mostly within the 
basement membrane. They can be assembled in many different oligomers [73] 
and represent another very important molecule of the ECM. On the one hand they 
facilitate the interaction of collagens and entactins by binding to them, and on the 
other hand they assist in the process of cell adhesion, thus supporting their 
capacity to form networks of molecules, rather than fibre-like structures (such as 
collagen). This gives the laminins the unique feature of resisting tensile forces that 
the cell membrane otherwise could not tolerate [74]. Furthermore, they are known 
to be involved in certain signaling events, thereby representing another member of 
the cell-ECM dialogue [75]. 
As mentioned earlier, bridge molecules connecting the cell´s cytoplasm and the 
ECM are mainly built by integrins. These transmembrane receptors are 
considered as the main player of cell-cell and cell-ECM interactions. Their ability to 
transduce a signal in both directions enables a cell to react to outside and inside 
stimuli [76]. Thus, a quick response to extracellular changes can be mediated into 
the cell directly via integrins (e.g. a certain ECM composition can initiate 
differentiation in certain cell types [77]). Integrins are also known to be associated 
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with and triggered by other ECM proteins such as collagen, laminin, fibronectin 
(introduced above), cadherin and several others. This highlights their central role 
in mediating a signal with regards to the ECM composition into the cell. Their 
intracellular functions include signal transduction by various second messenger 
systems, but also attachment to microfilaments has been described, thereby 
attaching the cytoskeleton of a cell directly to the ECM, which creates one 
interconnected network in- and outside of the cell [78]. All integrins consist of an α- 
and a β-subunit which together build a heterodimer which is biologically active. 
However, the variety of subunits is huge and depending on the composition of the 
integrin, different cellular functions can be found [79]. In conclusion, integrins 
nicely underline the central role of the ECM to determine a cells fate, future and 
status. A cell is not simply anchored to its ECM, but the crosstalk between the 
surroundings of the cell to the actions taken by the cell, highly depends on a tightly 
regulated mechanism that can lead to differentiation, apoptosis, growth, division 
etc. [80]. 
Lastly, the group of syndecans will be presented. They represent another 
important player in the cell-ECM crosstalk machinery. These proteins are single 
transmembrane domain molecules that can act as receptors. Importantly, upon 
ligand binding, they can induce a second messenger cascade in the cell which 
ultimately leads to transcriptional changes of the genome [81]. In contrast to other 
transmembrane proteins such as integrins, they are not bound to other ECM 
protein ligands, but they themselves are covalently bound to proteoglycans of the 
ECM (e.g. heparan sulfate and chondroitin sulfate). This makes them an exclusive 
member of the ECM itself. This feature further increases the amount of potential 
ligands to the syndecans, as many signaling molecules are known to be 
associated to proteoglycans (TGF-β, fibronectin, FGFs etc.) [82]. Cleavage of the 
ectodomain of a syndecan (a process called shedding) is an important regulatory 
step in signal processing of the cell towards outside stimuli. It was shown that 
syndecans can be specifically cleaved, thereby releasing a peptide that can in turn 
have stimulatory functions towards a cell [83]. Interestingly, certain diseases of the 
connective tissue show elevated levels of these cleaved syndecan ectodomains 
[84]. Very likely, syndecans are only one example for shedding with subsequent 
signaling events, as many ECM proteins exhibit specific extracellular cleavage 
sites, by for instance matrix metalloproteinases (MMPs) and the disintegrin and 
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metalloproteinases (ADAMs) [85, 86]. A total of four different syndecan family 
members have been described so far and the ratio, distribution and localization 
defines a cell´s specific sensitivity towards syndecan-related signals [81]. 
 
 
Figure 5: Schematic overview of the extracellular matrix (ECM). (© 
www.jonlieffmd.com) 
 
1.3.2 Reorganization of the ECM during stem cell commitment 
As mentioned previously, the crosstalk between a cell and its ECM is of great 
importance to determine cellular fate. As an example of this dialogue, this chapter 
will discuss the complexity of ECM reorganization during stem cell differentiation. 
As already discussed in chapter 1.1.1, the stem cell niche defines the cells 
character and reactivity towards specialization and differentiation. However, a 
stem cell undergoing differentiation reorganizes almost every aspect of its cellular 
strategy. Not only is the ECM an integral component of this reorganization, 
evidence now hints to the fact that it might even be an essential part of stem cell 
commitment towards a specific lineage [11, 87]. Thus, the ECM needs to be 
remodelled completely during the process of stem cell differentiation. Interestingly, 
evidence exists to support the notion that an extracellular input on certain cell 
types, induces a mechanosensitive response of the cell, leading to differentiation 
of stem cells towards, for instance, osteogenesis (stiff environment) or 
adipogenesis (loose environment). This sensing of the cell´s surrounding is 
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executed by multiple proteins of the ECM, which were introduced above [77, 88]. 
While these studies clearly showed that ECM stiffness and architecture has a 
direct effect on stem cell differentiation, the question remains as to what happens 
to the ECM of a multipotent stromal cell during differentiation. It seems obvious 
that a breakdown and rebuilding of the ECM must take place as well.  
Since it is known that many molecules such as hormones, growth factors and even 
molecules of the ECM itself can have an impact on cell signaling, the complexity of 
the ECM in a regulatory context becomes even greater. MMPs are prominent 
candidates of the ECM breakdown process [13, 14]. They are secreted from a cell 
when a reorganization of the ECM is needed, thereby generating a multitude of 
signaling peptides that are released by the ECM. These signaling molecules now 
can in turn have a positive or negative feedback effect on the cell. It is therefore 
crucial for the cell (or other cells in close proximity) to secrete the correct enzymes 
responsible for the breakdown of the ECM at the right time. It could otherwise 
have detrimental effects, resulting in a waste of energy and resources of the cell. A 
long list of specialized extracellular enzymes is necessary to guarantee successful 
ECM reorganization [11, 14, 89, 90]. 
While it is known that ectodomain shedding of several components of the ECM is 
regulated by MMPs and other extracellular proteases [85, 91-93], some MMPs 
themselves are subject to cleavage, which activates the enzyme and results in its 
maturation [94]. Furthermore, it is known that MMPs are involved in the acute 
inflammatory process of the connective tissue [95]. However, the detailed 
regulation of MMPs, their substrates and inhibitors, as well as MMP activation 
remains largely unknown, and it seems likely that they are involved in many more 
processes together with other proteases of the ECM. An overview about the best 
characterized MMPs, their function and inhibitors can be seen in figure 6. 
 
 
 
 
 
 
 
 
Introduction 
27 
 
 
 
Figure 6: An overview of MMP proteins, together with their function. (© 
Kdahlquist, Martin van Iersel 2008) 
 
The ADAMs metalloproteinase family is another example of a protein involved in 
ECM reorganization in multiple ways. Not only does it have a direct effect on the 
cells to stimulate MMP secretion, it also creates substrate breakdown products 
itself, which in turn activate different factors known to be involved in tumor 
progression [96]. A novel protease, called high temperature requirement serine 
protease A1 (HTRA1), was also found to be involved in ECM reorganization [97, 
98]. Although they are not members of the MMP family, which is the most 
prominent participant in ECM reorganization, both ADAMs and HTRA1 represent 
two examples of recently discovered proteases involved in ECM reorganization 
[86, 97]. This highlights the fact that ECM reorganization complexity has not yet 
been fully realized and it is likely that increasingly more candidates will be 
identified. 
Importantly, a naturally occurring equilibrium between proteases and their broad or 
specific inhibitors exists [99]. Hence, another regulatory level for substrate-enzyme 
reactivity is thereby created. Enzymatic activity on a certain substrate is therefore 
highly dependent on many factors involving both, enzyme and substrate. Here, 
events such as transcription, post-translational modification, molecular 
stoichiometry, protein inhibition/ activation etc. are important. This is why inhibitors 
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of certain extracellular proteases can have a positive or negative impact on 
disease progression or cell integrity [100]. For instance, the serpin peptide family 
represents a family of well-known inhibitors. They are capable of potently inhibiting 
a wide range of serine proteases and are known to be involved in a quick 
deactivation of many serine proteases, thereby regulating many extracellular 
processes, as for instance blood coagulation [101]. In conclusion, this highlights 
their potential involvement in reorganization of the ECM, making the tightly 
orchestrated machinery for ECM content homeostasis even more complex. 
1.4 HTRA1 
HTRA1 is a secreted peptidase involved in numerous intracellular and extracellular 
processes [102, 103]. HTRA1 is a protein found ubiquitously in almost every tissue 
of the human body [104] and is one of four so far described HTRA’s that together 
build a highly conserved family. The HTRA family members share several 
common domains including a protease domain and at least one PDZ domain [105, 
106]. A schematic overview of HTRA1 with its subdomains can be seen in figure 7. 
It is believed that alterations in HTRA1 activity are involved in the onset and 
progression of many diseases such as cancer, CARASIL, rheumatic disorders, 
and intervertebral disc (IVD) degeneration [107-109]. Still, its detailed mode of 
action remains largely unknown. However, many features have been well 
described and will therefore be highlighted here. 
1.4.1 Structural properties 
With the help of state-of-the-art techniques such as crystallography and stopped 
flow, it was possible to determine the exact architecture of HTRA1 either in the 
absence or presence of a substrate. We can therefore now distinguish between 
five distinct domains within the primary structure of the HTRA1 molecule: 
 Signal sequence 1.4.1.1
The N-terminal signal sequence is a feature found in mammalian HTRA1, -3 and -
4. These three members of the HTRA family are all known to be secreted from the 
cell and hence, have to carry a signal sequence for the initiation of the protein´s 
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secretion. Thus, the signal sequence is very likely crucial to the directed secretion 
of HTRA1 from the cell. However, the detailed mechanism of the secretion 
pathway of HTRA1 remains largely unknown [110]. 
 IGFBP/Mac25 domain 1.4.1.2
This domain is termed the Mac25 domain due to structural similarities to IGFBP 
(insulin-like growth factor-binding protein) domains. Surprisingly, no direct 
interaction of this domain to IGFs has so far been shown, suggesting that the 
domain may have an entirely different mode of action. Similarly, the term Mac25-
domain remains misleading, as also the similarity to the Mac25 protein (a follistatin 
(FS)-like protein) did not show any functional similarities to FS-like proteins at all 
[110]. Thus, the function of this domain remains largely unknown, as it does not 
seem to have any impact on proteolytic activity either [111, 112]. However, it was 
proposed that HTRA1 may have two different ways of identifying its potential 
substrates. The most prominent one being a direct recognition of the substrate 
with the help of the PDZ domain (c.f. 1.4.1.5) in order to allow for proteolysis to 
occur. The other one is the IGFBP/Mac25 domain which potentially helps to bind 
and cleave, for example, IGFBP-5 and thereby to regulate IGF signaling [113]. 
Furthermore, it was also shown that the alteration of the TGF-β pathway by 
HTRA1 is dependent on both proteolytic activity and the presence of the preceding 
region to the protease domain [114], thereby strengthening the importance of this 
sequence with regards to HTRA1’s substrate specificity. Nevertheless, the details 
about this domains’ importance have yet to be elucidated. 
 Kazal-type serine protease inhibitor domain 1.4.1.3
Interestingly, upstream of the protease domain, a Kazal-type serine protease 
inhibitor domain (Kazal domain) can be found. This domain is known to inhibit 
serine proteases specifically by binding to the proteolytically active domain and 
thereby inhibiting substrate binding. It is often found next to the IGFBP-like domain 
described above. Due to its close proximity to the HTRA1 protease domain, it is 
likely to be inhibitory during the resting state of HTRA1 in the absence of any 
substrate, although its inhibitory effect could so far not be shown [112, 115, 116]. 
However, the combination of the IGFBP/Mac25 and Kazal domain is found in 
many proteins, although their functional implications remain unknown [117]. 
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Hence, it could be part of the zymogen status of the non-active enzyme, which 
prevents it from premature activation and hints to the idea of maturation induced 
by cleavage by other proteases or auto-cleavage. 
 Protease domain 1.4.1.4
HTRA1 exhibits the classical composition of a trypsin-like serine endopeptidase. 
The term trypsin-like refers to a subset of serine proteases that cleave peptide 
bonds following a positively charged amino acid (a lysine or arginine) in the target 
protein, which gives them their specific nomenclature. The specificity of the 
protease domain to its substrates is given by the composition of the catalytic triad, 
the secondary structure of the enzyme´s proteolytic pocket and its amino acid 
residues, as well as by other domains of the enzyme (e.g. a PDZ domain) [102]. 
As in most serine proteases, the catalytically active region consists of a highly 
conserved domain where the proteolytic activity of the enzyme takes place. 
Proteolytic activity refers to the process of the enzymes ability to cleave peptide 
bonds within a protein, making it an endopeptidase. The name serine protease 
derives from the fact that a serine residue within the catalytic triad of the protease 
domain is responsible for the nucleophilic attack of the carbonyl group of the 
peptide bond, thereby erasing a covalent bond which results in the separation into 
two individual peptides [118]. 
 PDZ domain 1.4.1.5
The C-terminus of HTRA1 carries a post-synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein 
(zo-1) domain (PDZ-domain). Generally, its function is to provide substrate 
specificity towards many different proteins. This is accomplished in a very directed 
manner, which is why the PDZ domain also represents a highly conserved 
domain, being similar in many PDZ-domain carrying proteins, but highly specific 
for a group of target proteins [119]. This is brought about via a distinct sequence 
specificity of the PDZ domain towards its targets [120]. Thousands of proteins with 
many different functions are known to carry a PDZ-domain whenever substrate 
specificity is needed [121]. Due to their complexity, PDZ-substrate interactions are 
a critical factor in many processes and diseases of the cell and even the body as a 
whole. Predicting potential targets of a known PDZ-domain sequence could 
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therefore help to understand many processes in- and outside of the cell [121]. The 
PDZ domain of HTRA1 and its specificity is well described by Truebestein et al 
[111]. However, other HTRA proteins may carry one or multiple PDZ domains of 
different specificities. Furthermore, the PDZ domain is described to represent a 
bottleneck of enzymatic activity, as the binding of the substrate to the PDZ-domain 
induces a conformational change of the whole HTRA1 enzyme, which allows the 
protease domain to execute its function, which would otherwise be sterically 
blocked [110, 122]. However, recent findings indicate that PDZ-domain lacking 
mutants of HTRA1 only show a marginal decrease in enzymatic activity (c.f. 
section 4). 
As HTRA1 is also known to be secreted from certain cell types, it may seem 
surprising to find a PDZ domain on the C-terminus of HTRA1, as PDZ-domain 
have mostly been described intracellularly [119]. In conclusion, the PDZ domain of 
HTRA1 provides substrate specificity and induces a conformational change upon 
substrate binding, thereby allowing enzymatic activity to occur [111, 123]. 
 
 
Figure 7: Overview about the functional domains of human HTRA1 [124]. 
 
 Oligomerization 1.4.1.6
Although a single molecule of HTRA1 is soluble and stable, higher hierarchies of 
HTRA1 oligomerization have been described and are likely to coexist upon 
different environmental conditions [111]. Especially homotrimers appear to be the 
most abundant form of HTRA1 protein, although in vitro tests indicate even higher 
oligomeric states (c.f. section 4). This oligomeric state was found to be increased 
drastically in the bacterial homologues of HTRA1 (DegP [125]), but is also found in 
mammalian HTRA1 and is thought to be a key feature of activation and 
deactivation of HTRA1 proteolysis [126]. While usually three protease domains are 
capable of forming a trimer, higher assembly hierarchies are also facilitated by 
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PDZ-PDZ interactions. It is believed that the homotrimer state corresponds to a 
resting state of HTRA1, whereas 12- and 24-mers are believed to be involved in 
the functions of HTRA1 with regards to protein quality control and stress response 
of the cell [126]. Findings of Truebestein et al (2011) also suggest that the 
protease domain of several HTRA1 molecules assemble, thereby creating a 
barrel-like structure which exhibits an increased enzymatic activity [111]. However, 
it is questionable if this oligomeric state is of a high physiological relevance, as 
most other HTRA proteins and their homologues exhibit a higher activity at higher 
oligomeric states, thereby creating huge barrel-like structures which are believed 
to facilitate the chaperone and proteolytic activity of the protease [123, 127]. Thus, 
the oligomeric status of HTRA1 and other HTRA family members is likely to be an 
additional layer of regulating protease activity and helps to discriminate between 
the mere proteolysis and its involvement in acute protein quality control. 
1.4.2 Functional implications 
The mode of action of HTRA1 can be divided into two main categories: 
 
1. Binding to a substrate in- or outside of the cell and thereby stabilizing, 
destabilizing (microtubule association) [128], inhibiting or activating certain 
factors [107, 114]. 
2. Degradation of target molecules by its enzymatic activity and thereby 
creating signaling molecules (e.g. syndecan shedding) or physically 
breaking down molecules (e.g. fibronectin in the ECM) [129]. 
 
Found as a heat shock induced chaperone in bacteria [130], the chaperone 
function (stabilization of otherwise non-stable and insoluble peptides) remains to 
be demonstrated in mammalian cells. Despite this, HTRA1’s involvement in 
numerous mammalian cell processes has been well described, and range from 
intracellular functions [105] to extracellular secretion from the cells where it might 
fulfil different tasks. This clearly highlights its various functions and implications in- 
and outside of the cell with many potential involvements in diseases [117]. 
However, details on its role in the stress response of the mammalian cell appears 
to be less well understood, as HTRA1 secretion is increased as a response to heat 
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shock conditions [102]. Under these conditions it can efficiently degrade heat-
sensitive proteins that could otherwise be a threat to the survival of the cell. Still, 
recent studies highlight the importance of HTRA1 in developing tissues, which 
would confirm its importance in the process of ECM reorganization [104]. 
It is therefore important to distinguish between HTRA1´s basic functions intra- and 
extracellularly, as these very different compartments vary in the protein quality 
control machinery and many other aspects. 
1.4.3 Involvement in developing tissues 
Expression profile studies of the HTRA1 gene revealed an upregulation in 
developing tissues and organs [131]. Especially the placenta (an area of high 
proliferation rates and stem cell activity) shows a significant upregulation of 
HTRA1 and a loss of HTRA1 in this tissue was shown to have a negative impact 
on tissue development [131-133]. Hence, it appears that HTRA1 is necessary in 
regions that require highly dynamic cellular restructuring processes. Indeed, it has 
been shown that a lack of HTRA1 results in an abnormal development of the 
placenta in mice [133]. In conclusion, the developing placenta is likely to be a 
prominent example of the necessity of HTRA1 and other proteases to be directly 
involved in the development of a tissue. 
1.4.4 Intracellular function 
 Association to tubulin 1.4.4.1
Intracellularly, HTRA1 is highly localized to microtubules in mammalian cells [128]. 
Although it is not clear what function this may serve, it was demonstrated that 
HTRA1 overexpression resulted in inhibition of cell migration, which would indicate 
a tumor suppressor-like function of HTRA1 [134]. However, while low 
concentrations of HTRA1 are able to stabilize microtubule polymerization in vitro, 
higher concentrations seem to have no effect on stability. Furthermore, HTRA1 
was found to degrade tubulin in vitro [135]. 
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 TSC2 1.4.4.2
Moreover, other intracellular components were found as direct targets of HTRA1. 
The protein tuberous sclerosis complex 2 (TSC2) is known to be a negative 
regulator of the mTOR pathway, is involved in embryogenesis and was shown to 
be a direct target of HTRA1. Upon degradation by HTRA1, downstream targets of 
the TSC2 pathway are effectively inhibited. Since it is known that HTRA1 is 
upregulated in developing tissues of the embryo, TSC2 could be an example of 
one of many potential HTRA1 targets inside of the cell during development [136]. 
 XIAP 1.4.4.3
The X-linked inhibitor of apoptosis protein (XIAP) is an important inhibitor of 
apoptosis. It was recently shown that HTRA1 may be directly involved in regulating 
the intracellular amounts of this factor by degrading it, thereby actively down-
regulating apoptosis [137, 138]. Thus, a direct involvement in cancer progression 
and chemotherapy resistance is postulated. 
1.4.5 Extracellular function 
As mentioned earlier, HTRA1 is known to be secreted in various conditions, be it 
stress-response, inflammation and disease or the differentiation of stem cells [109, 
139, 140]. Therefore, it was not surprising to find it involved in the regulation of 
several processes, including joint degeneration [107], cancer progression and 
several others [141, 142]. Due to its ability to potentially cleave several 
components of the ECM [143], it appears obvious that a tight regulation of HTRA1 
during development and rearrangement of a tissue is needed in order to maintain 
tissue integrity and health. HTRA1 can therefore potentially be seen as an 
essential developmental factor during many transition conditions of a cell or even 
tissue. However, its detailed mode of action remains largely unknown, as well as 
its regulatory pathways of expression and secretion. Known substrates for 
extracellular HTRA1 are, amongst others, fibronectin [129], aggrecan [144], type II 
collagen [145], elastin, biglycan, syndecan-4, nidogen [146], glypican-4 [97], all of 
which are important for specific ECM integrity (c.f. section 1.3). Potentially, the list 
of substrates for HTRA1 is even greater [143]. However, next to its proteolytic 
activity, HTRA1 was also shown to have signaling effects on cells, resulting in an 
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upregulation of MMPs, independent of HTRA1 proteolytic activity [107]. 
Transforming growth factor-beta (TGF-β) signaling is inhibited by HTRA1. This 
cytokine is secreted by various cell types and controls many cellular processes 
such as differentiation and proliferation [147]. Due to its possible association to 
HTRA1, TGF-β signaling can be inhibited, thus inhibiting receptor activation of 
various TGF-β ligands, as described by Oka et al [114]. This represents an 
example of how HTRA1´s extracellular presence can affect an intracellular 
pathway of a developing cell, thereby connecting the in- and outside functions of 
HTRA1 on the cell. However, recent reports identified HTRA1 as being a 
stimulatory factor towards TGF-β signalling under certain conditions, by the 
degradation of latent TGF-β binding protein 1 (LTBP1) [148]. 
1.4.6 HTRA1 in disease 
To further highlight the importance of HTRA1 in heath and disease, some of the 
best studied human diseases in which HTRA1 is implicated as being an underlying 
cause are described in the following chapter. 
 AMD 1.4.6.1
The disease age-related macular degeneration (AMD) is a medical condition of the 
eye, which results in blindness. It occurs in a dry and wet (also referred to as 
neovascular AMD) state in which the retina loses its function over the progression 
of the disease. It was found that genetic variants, leading to loss-of-function 
mutations of HTRA1 protein, could be the underlying cause in the onset of this 
disease. Here, HTRA1´s ability to act on TGF-β signaling due to the degradation of 
TGF-β pathway members seems to be the mechanism of action [149-151]. On the 
other hand, it was shown that mutations in the promoter region of HTRA1 (as well 
as ARMS2) can lead to an upregulation of HTRA1 expression, which ultimately 
leads to an increased proteolytic activity in the ECM of the affected tissue. This 
can therefore lead to structural changes of the ECM, which results in AMD 
progression [146]. 
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 Cancer  1.4.6.2
Several studies have investigated the influence of HTRA1 on cancer progression. 
Increasing awareness towards an involvement of the ECM in cancer and other 
cellular processes acknowledges the fact that the rearrangement of the ECM can 
have a major impact on cancer progression. It is generally accepted that HTRA1 
levels in cancerous tissue are significantly down regulated, thereby suggestive of 
HTRA1´s role as a tumor suppressor [141]. However, the influence of HTRA1 on 
cancer progression goes beyond its activity on ECM components and includes 
intracellular cytoskeletal deficiencies [134], as well as chemotherapy resistance 
[138]. Generally, it appears that the expression levels of HTRA1 in certain cancer 
types are dysregulated, more than the activity of HTRA1 itself [152, 153]. 
However, more functional analyses are needed to fully investigate this. Thus, the 
mutual crosstalk between HTRA1 and its many substrates and binding partners 
can result in a diverse range of conditions, in which the cell tends to further 
progress in its malign status. Furthermore, expression levels of certain inhibitory 
molecules can have an important role as recent studies have shown. One example 
is given by serpin alpha-1 antitrypsin (A1AD), which was found to be a target of 
HTRA1 [100]. 
 CARASIL 1.4.6.3
Next to AMD and different types of cancer, loss-of-function mutations in the 
HTRA1 gene were also found to be the underlying cause of certain neurological 
disorders, such as Cerebral Autosomal-recessive Arteriopathy with Subcortical 
Infarcts and Leukoencephalopathy (CARASIL). In this rare disease, mutations in 
the HTRA1 gene lead to errors in the TGF-β signaling cascade, which ultimately 
leads to dysfunctional arterioles of the brain resulting in reoccurring strokes of the 
brain tissue. Although the disease was described in only a small group of patients, 
it stresses the diverse impact that dysfunctional HTRA1 protein can have in 
different types of tissues throughout the body [154, 155].  
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 Alzheimer’s disease 1.4.6.4
There is conflicting data concerning the involvement of HTRA1 in Alzheimer’s 
disease. While a study by Grau et al (2006) confirmed HTRA1 to be involved in the 
processing of the amyloid precursor [156], another study found no association 
between HTRA1 gene polymorphism and Alzheimer’s [157]. Hence, if HTRA1 is 
involved in the progression of this particular disease, this involvement is, contrary 
to many other disease conditions as for instance cancer, not based on a genetic 
variant of HTRA1 itself but could involve many other candidates (e.g. enzyme-to-
substrate ratio, enzyme inhibition etc.). However, the involvement of HTRA1 in 
Alzheimer´s disease is likely when considering the characteristics of the disease to 
be caused by protein aggregates, called plaques. A dysregulation of HTRA1 
activity could therefore facilitate plaque formation and hence, disease progression. 
Thus, further investigations are needed. 
 Musculoskeletal Diseases 1.4.6.5
The term musculoskeletal disease (MSD) comprises muscle and bone tissue, as 
well as connective tissue associated to it in the human body. Together they make 
up a wide variety of tissues, including joints, bones, muscles, cartilage, tendon and 
ligaments. Diseases in any of these tissues can drastically affect the mobility of an 
individual and is known to affect millions of people worldwide. Contrary to cancer, 
many diseases of the connective tissue are caused by increased levels of 
secreted HTRA1 by the surrounding cells [109, 158] as is the case in OA and IVD 
disease [107, 129, 159, 160]. 
With regards to its role in MSD, HTRA1 was initially identified as having a potential 
role in Duchenne muscular dystrophy (DMD). This disease results in muscle 
degeneration and can even lead to a premature death. Although no functional 
studies about HTRA1 activity have yet been performed, a study exists in which 
HTRA1 expression levels were significantly increased in the muscle tissue of a 
patient with DMD. It was speculated that HTRA1 could act on insulin-growth factor 
binding protein 5 (IGFBP5), which it can deactivate by degradation. A lack of 
IGFBP5 in the muscle is known to be an underlying cause of DMD, which is 
needed for proper muscle development and maintenance by insulin-growth factor-
1 (IGF-1) augmentation [113, 161]. 
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It is of note that the involvement of HTRA1 in bone development has been under 
investigation for several years now [124, 162, 163]. It still remains controversial as 
to how it may potentially influence bone formation due to several studies reporting 
both positive and negative effects of HTRA1 on osteogenesis [163, 164]. An early 
in vitro study performed by Hadfield et al [179] resulted in HTRA1 being labeled as 
an inhibitor of osteoblast differentiation. However, the detailed mechanism 
underlying this regulatory process of HTRA1 on bone formation remains an open 
question. Somewhat in contrast to these findings, molecular- and histological-
based studies in mice have demonstrated high levels of HTRA1 to be present in 
osteoid and newly formed bone [114, 162]. Furthermore, HTRA1 loss-of-function 
studies in hMSCs undergoing osteogenic differentiation resulted in impaired 
osteoblast-derived mineral formation [165]. However, a more recent study by 
Graham et al [163] demonstrated an anti-osteogenic effect of HTRA1 in vitro and 
in vivo, and this was considered to be primarily due to its ability to cleave TGF-β 
receptors thereby disrupting TGF signaling pathways. However, more studies 
confirming this effect need to be conducted.  
It should be mentioned that most of the studies described above were conducted 
in immortalized cell lines and may not be representative of primary bone-forming 
cells, as is the case in the study performed by Tiaden et al [165]. In addition, 
findings by Oka et al (2004) identified a number of HTRA1 substrates both in vitro 
and in vivo, the most important ones being members of the TGF-β family [114], 
with implications for the bone development process [163, 166]. Interestingly, the 
TGF-β signaling cascade is also known to be involved in adipogenesis, although 
its detailed mode of action remains largely unknown [167], thus implying a 
potential role for HTRA1 in differentiation pathways other than osteogenesis. This 
assumption is further highlighted by the fact that the secretion of proteases, such 
as HTRA1, can restructure the ECM and thereby have an impact on stem cell 
commitment towards osteogenesis or adipogenesis [168-170]. In conclusion, 
HTRA1 protein and gene expression have successfully been shown to be the 
underlying cause of many different diseases affecting the connective tissue, as 
well as in the process of cellular maturation and differentiation [109, 124, 162, 164, 
171]. This is most likely due to a combination of both HTRA1´s proteolytic activity 
and its ability to bind and thereby disrupt critical signaling events (a central one 
being TGF-β) [124, 148, 166]. 
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Thus, despite the fact that HTRA1 was long seen as a factor contributing to certain 
MSDs, it is important to understand that other conditions may require a fully 
functional protease like HTRA1 to be active in the ECM in order to allow for 
healthy tissue development and maintenance [109]. In conclusion, many MSDs in 
which a turnover of the ECM has an effect on disease onset or progression rely on 
the absence or presence of HTRA1 and other proteases (e.g. MMPs). 
Undoubtedly, the number of MSDs involving HTRA1 as being a positive or 
negative regulator will therefore increase over the next years. 
1.5 Conclusion 
Stem cells hold great promise as future therapeutic strategies in regenerative and 
preventive medicine. The fact that stem cells can themselves differentiate into any 
known cell type and thereby even allow the development of an entire organ in an 
autologous manner, makes them an attractive target for medical research in many 
given areas. As such, a full understanding of stem cell differentiation is an 
absolute requirement and would undoubtedly allow for the optimized use of stem 
cells in biomedical and therapeutic applications of many different kinds. It is now 
well acknowledged that osteogenesis and adipogenesis are regulated reciprocally 
on many levels [19, 172-175] and that imbalances in these two processes can 
contribute to the development of debilitating disorders such as osteoporosis. 
Identifying these factors could therefore represent a major breakthrough in fighting 
these diseases, as well as in understanding the fundamental stem cell 
differentiation process in more detail. HTRA1 may represent one such factor, 
based on its ability to regulate osteogenesis [124, 164], although its impact on 
other lineage pathways has not yet been fully investigated.  
 
Therefore, in the realms of this thesis, the influence of extracellular HTRA1 on 
hMSC lineage commitment is addressed, with a predominant focus on its role in 
hMSC adipogenesis. 
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2 Hypothesis and aims of the thesis 
The primary premise of the current study is that HTRA1 acts as a negative 
regulator of adipocyte development in differentiating human MSCs, and that these 
effects can help establish its potential role in fat homeostasis in both health and 
disease. This hypothesis is tested by fulfilling the following aims: 
 
Aim 1: Express and purify active and inactive forms of recombinant human HTRA1 
using an E.coli expression system. 
Aim 2: Examine the effects of exogenous HTRA1 and siRNA-mediated HTRA1 
silencing on human MSC adipogenesis 
Aim 3: Established a mechanism of action for HTRA1 with regards to its ability to 
influence human MSC adipocyte development 
Aim 4: Validate the relevance of HTRA1’s involvement in regulating human MSC 
adipogenesis in health and disease 
 
It is envisaged that the results generated from this study will enhance our 
understanding of the role played by the serine protease HTRA1 in the adipogenic 
differentiation of human MSCs and subsequently allow us further insight into the 
intricacies governing this process. Furthermore, our findings may have significant 
relevance with regards to fat homeostasis, whereby dysregulation of adipocyte 
formation and function are considered to be key events in the development of 
various disorders including diabetes type II and osteoporosis. 
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3 Results 
3.1 Overview of published and submitted manuscripts 
 
3.1.1 Novel function of serine protease HTRA1 in inhibiting adipogenic 
differentiation of human mesenchymal stem cells via 
MAP kinase-mediated MMP upregulation. 
Authors:  Tiaden AN*, Bahrenberg G*, Mirsaidi A, Glanz S, Blüher M, 
Richards PJ. 
*authors contributed equally 
Journal: under review by Stem Cells (August 2015) 
Contribution: Execution of recombinant HTRA1 protein production and in vitro test 
(Fig. S1B+C, S3), ELISA (Fig. 2G, 3E+F, 5C+D), qPCR (Fig. 3 A-D, 
6B+C, S4C-E), FACS (Fig. 2A-F, S2), oil red staining and 
quantification (Fig. 1B-D, 5E+F, 6D, S4F), FN in vitro studies (Fig. 
S4A+B, S5C+D), Western blots (Fig. 6A). Planning, evaluation of the 
study. Writing of materials and methods and discussion section. 
 
3.1.2 Use of biomimetic microtissue spheroids and specific growth factor 
supplementation to improve tenocyte differentiation and adaptation 
to a collagen-based scaffold in vitro. 
Authors:  Theiss F, Mirsaidi A, Mhanna R, Glanz S, Bahrenberg G, Tiaden 
AN, Richards PJ. 
Journal: Biomaterials 2015 Aug 10;69:99-109 
Contribution: Planning, execution and evaluation of the cell culture and molecular 
biology aspects, i.e. cell culture work, qPCR (Fig. 4+5). Contribution 
to writing of discussion section. 
 
 
Results 
44 
 
 
3.1.3 Human serine protease HTRA1 positively regulates osteogenesis of 
human bone marrow-derived mesenchymal stem cells and 
mineralization of differentiating bone-forming cells through the 
modulation of extracellular matrix protein. 
Authors: Tiaden AN, Breiden M, Mirsaidi A, Weber FA, Bahrenberg G, Glanz 
S, Cinelli P, Ehrmann M, Richards PJ. 
Journal: Stem Cells. 2012 Oct;30(10):2271-82. 
Contribution: Execution of recombinant HTRA1 protein production, qPCR (Fig. 
1A), oil red staining (Fig. 1B, 2D+E, 3C, Fig. 4A-D). Planning, 
evaluation of the study. 
3.1.4 Detrimental role for human high temperature requirement serine 
protease A1 (HTRA1) in the pathogenesis of intervertebral disc (IVD) 
degeneration. 
Authors: Tiaden AN, Klawitter M, Lux V, Mirsaidi A, Bahrenberg G, Glanz S, 
Quero L, Liebscher T, Wuertz K, Ehrmann M, Richards PJ. 
Journal: J Biol Chem. 2012 Jun 15;287(25):21335-45. 
Contribution: Execution of recombinant HTRA1 protein production and in vitro 
studies (Fig. 2A+B). qPCR (Fig. 2C-F, 3D), Western blots (Fig.4 A-
C). Planning, evaluation of the study. 
3.1.5 Assessment of the Matrix Degenerative Effects of MMP-3, ADAMTS-4 
and HTRA1 injected into a bovine Intervertebral Disc Organ Culture 
Model. 
Authors: Furtwängler T, Chan SC, Bahrenberg G, Richards PJ, Gantenbein-
Ritter B. 
Journal: Spine (Phila Pa 1976). 2013 Oct 15;38(22):E1377-87. 
Contribution: Execution of recombinant HTRA1 protein production. 
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4 Unpublished data 
As described by Tennstaedt et al (2012), recombinant HTRA1 protein was 
overexpressed and purified from bacteria [112]. To confirm the purity of the final 
protein, 4 µg of each protein was loaded on a SDS-PAGE gel and stained with 
Coomassie Blue (Fig. 8). A total of 4 µg of BSA was also used as a loading 
control. 
 
 
                           
Figure 8: Coomassie Clue stained SDS-PAGE of 4µg protein per lane. 1 = 
ΔMac; 2 = ΔMacSA; 3 = ΔMac/ΔPDZ; 4 = ΔMacSA/ΔPDZ; 5 = ΔMac/Δprotease; 6 
= BSA (loading control). 
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As purified recombinant protein was to be subsequently used under sterile cell 
culture conditions, LPS content had to be in a range suitable for cell culture 
systems. Hence, a LPS test was performed for all constructs purified before they 
were used in cell culture (Pierce LAL Chromogenic Endotoxin Quantitation Kit, 
Thermo Scientific). Figure 9 shows a representative measurement of the LPS 
content of three recombinant HTRA1 constructs, as well as of the αLG4-5 
construct (Fig. 18). Since the FDA’s guideline allows a maximum endotoxin level 
of up to 0.25 EU/ml, all samples tested are applicable for cell culture usage [176]. 
Conclusively, the recombinant proteins tested can even be considered endotoxin-
free, as the detection limit of the assay used lies in the range of approximately 
0.05 EU/ml.  
 
 
          
Figure 9: Representation of the LPS-content of the recombinant protein 
samples used in cell culture. 
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In a next step, recombinant HTRA1 and HTRA3 protein constructs were used in a 
proteolytic assay set up (c.f. [177]) to determine their protease activity towards 
BODIPY-FL-labeled DQ elastin conjugate using the EnzChek Elastase Assay Kit 
[177] (Fig. 10 and 11). All constructs carrying an active proteolytic domain showed 
a time-dependent increase in fluorescence, thereby indicating cleavage of the 
elastin substrate. At the same time, all inactive constructs exhibited almost no 
cleavage of elastin at all (Fig. 10). 
 
 
      
Figure 10: Time course of the protease activity assay with different 
recombinant HTRA1 and HTRA3 constructs. 
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In the same set up, HTRA1, HTRA3 and trypsin were incubated with BODIPY-FL-
labeled DQ elastin conjugate in the absence or presence of a specific HTRA1 
antibody (10 µg/ml, antibody kindly provided by Novartis). It was shown that the 
presence of the antibody resulted in a significant decrease of HTRA1 activity 
(p<0.001 after 4 h), while HTRA3 (p=0.24 after 4 h) and trypsin (p=0.05) activity 
remained unaltered or was even slightly increased (Fig. 11). 
 
 
      
Figure 11: Time course of the protease activity assay with recombinant 
HTRA1, HTRA3 and trypsin protein, with and without anti HTRA1 antibody 
(10 µg/ml). 
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To clarify the oligomeric status of different recombinant HTRA1 constructs, a Blue-
Native-PAGE gel was performed (Fig. 12). While the HTRA1ΔMac protein 
constructs under denatured conditions showed only one distinct band, native 
conditions revealed at least five different species of oligomeric states for this 
construct. The same was true for the ΔMac/ΔPDZ domain of HTRA1. At the same 
time, the ΔMac/Δprotease domain showed only one band at the predicted size of 
approximately 18kDa. 
 
 
              
Figure 12: Coomassie Blue stained Blue-Native-PAGE gel of the different 
HTRA1 recombinant constructs. 1 = HTRA1ΔMac; 2 = HTRA1ΔMac + 0.1% 
SDS (Sodium dodecyl sulfate); 3 = HTRA1ΔMac + 1% SDS; 4 = HTRA1ΔMacSA; 
5 = HTRA1ΔMac/ΔPDZ; 6 = HTRA1ΔMacSA/ΔPDZ; 7 = HTRA1ΔMac/Δprotease. 
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Figure 13 shows the result of a WST-1 assay performed with cells that were 
undifferentiated, differentiated and untreated, or differentiated and treated with 
recombinant active HTRA1ΔMac. No significant differences were observed, which 
serves as proof that the seen effects of HTRA1 not due to a decrease in cell 
proliferation and survival. 
 
 
              
Figure 13: WST-1 assay of cells treated with or without recombinant HTRA1 
protein and heparin for 21 days. 
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Furthermore, a first known cleavage substrate of HTRA1 was tested with the 
recombinant protein produced within this thesis. The digestion of the substrate 
fibronectin (FN) was evaluated when incubated over night with HTRA1ΔMac at 
37°C (molar ratio of 2:1) (Fig. 14). It was found that HTRA1 could cleave 
fibronectin in this in vitro set up. 
 
 
                
Figure 14: Coomassie Blue stained gradient SDS-PAGE gel of the fibronectin 
digestion by HTRA1ΔMac and HTRA1ΔMacSA. 1 = 5 μg HTRA1ΔMac and 10 
μg FN; 2 = 5 μg HTRA1ΔMac; 3 = 10 μg FN; 4 = 5 μg HTRA1ΔMac of old batch 
and 10 μg FN; 5 = 5 μg HTRA1ΔMacSA and 10 μg FN; 6 = 5 μg HTRA1ΔMacSA; 
7 = 5 μg retained HTRA1ΔMacSA from 50 kDA cutoff Amicon and 10 μg FN; 8 = 5 
μg retained HTRA1ΔMac from 50 kDA cutoff Amicon; 9 = 5 μg retained 
HTRA1ΔMacSA from 50 kDA cutoff Amicon. 
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Similarly, the stability of recombinant HTRA1ΔMac under different conditions was 
evaluated. For this, 3 µg of the recombinant protein was loaded on a SDS-PAGE 
gel either freshly, or subsequent to an overnight incubation at 37°C with or without 
CaCl2 (5 mM) (Fig. 15). It was found that HTRA1 was partially degraded when 
incubated over night at 37°C, and the presence of CaCl2 increased this effect. The 
same observation holds true with the activity of HTRA1 towards FN. 
 
 
 
 
                      
Figure 15: Coomassie Blue stained SDS-PAGE of a stability test of 
recombinant HTRA1 protein (3 µg per lane) and fibronectin. 1 = HTRA1ΔMac; 
2 = HTRA1ΔMac o/n 37°C; 3 = HTRA1ΔMac o/n 37°C + CaCl2 (5 mM); 4 = 
HTRA1ΔMac + FN; 5 = HTRA1ΔMac + FN + CaCl2. 
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Next to fibronectin, we looked at the involvement of other cellular surface proteins 
potentially involved in the adipogenesis. CD105 (endoglin) is one example of a 
known binding partner of the TGF-β pathway and is therefore another potential 
candidate for degradation by HTRA1, either actively or passively (e.g. MMPs) 
[178]. We therefore performed an in vitro digestion assay of HTRA1ΔMac and 
CD105 (molar ratio of 1:5; recombinant CD105 was obtained from R&D Systems) 
(Fig. 16). Several weakly stained CD105 fragments were observed following 
HTRA1 treatment as determined by Western blot analysis. Heparin, an agent used 
to inhibit HTRA1´s binding ability to the cell surface [177] was included in order to 
look at a potential inhibition or activation towards HTRA1´s proteolytic activity. 
However, the inclusion of heparin (purchased from SIGMA-ALDRICH) in this 
reaction had no impact on the proteolytic activity of HTRA1 towards CD105. It 
therefore appeared that HTRA1 has a minimal proteolytic activity towards CD105. 
 
 
                    
Figure 16: anti CD105-Western blot of the in vitro digestion of recombinant 
CD105 by HTRA1ΔMac. Heparin (hep) was added to the reaction in a 
concentration range from 0.1 to 10 µg/ml. 
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In order to further clarify HTRA1’s influence on CD105, hMSCs were incubated 
with HTRA1ΔMac and CD105 staining (PE anti-human CD105, BioLegend) was 
evaluated by FACS analysis (c.f. [177]) (Fig. 17). However, no significant effects 
on CD105 surface staining could be observed, thereby confirming HTRA1’s lack of 
proteolytic activity towards CD105. 
 
 
                   
Figure 17: Histogram of hMSCs treated (black line, no fill) or untreated (grey 
fill) with HTRA1ΔMac prior to the staining of CD105 with a fluorescently 
labeled antibody [177]. 
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Whilst analysing cell supernatants for additional sources of ECM fragments, we 
noticed that as compared to undifferentiated hMSCs, the supernatants of 
adipogenic hMSCs harboured less soluble laminin-α4, which appeared as ~ 45- 
and 65 kDa-bands following immunoblotting (Fig. 18). Moreover, supernatants 
harvested from adipogenic hMSCs treated with HTRA1∆Mac, but not with 
HTRA1∆MacSA, contained at least two additional laminin-α4 fragments, observed 
as bands at ~ 42 and 24 kDa. This was considered to be of particular relevance 
with regards to adipogenic induction based on the findings of a previous study in 
which laminin-α4 fragments containing the globular regions αLG4-5 were shown to 
have a negative influence on adipogenesis [179]. 
 
                                             
Figure 18: HTRA1 generates reactive ECM fragments. Western blot analysis of 
native laminin-α4 in concentrated supernatants harvested from undifferentiated 
hMSCs (control), untreated adipogenic hMSCs, or adipogenic hMSCs treated with 
recombinant HTRA1∆Mac (45 nM) for 2 days. Arrows indicate specific laminin-α4 
fragments due to HTRA1∆Mac treatment. 
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Furthermore, HTRA1∆Mac was able to generate similar sized fragments when 
incubated with a recombinant form of laminin-α4 (Fig. 19). 
 
                                  
Figure 19: Equimolar concentrations (225 nM) of recombinant laminin-α4 (rL-
α4) and recombinant HTRA1 were incubated together overnight at 37oC, and 
total protein separated by SDS-PAGE and analysed with Coomassie staining. 
Arrows indicate specific laminin-α4 fragments due to HTRA1∆Mac treatment. 
 
 
 
In order to gain deeper insights into this specific fragment produced by HTRA1, 
N-terminal sequencing of the 42 kDa fragment was performed and revealed a 
cleavage site between V1442 and A1443 within the linker region adjoining globular 
regions αLG3 and αLG4-5 (Fig. 20), thereby verifying that this fragment is 
produced specifically by the actions of HTRA1. 
 
 
 
 
 
25 
37 
50 
100 
150 
75 
Unpublished data 
211 
 
 
 
                                    
 
Figure 20: Amino acid sequence of laminin-α4 linkage region between αLG3 
and αLG4-5 indicating the HTRA1 cleavage site as determined by N-terminal 
sequencing (arrow head). 
 
 
Since we hypothesized that the αLG4-5 fragment produced by HTRA1 was 
reactive towards hMSC adipogenesis, we generated a purified recombinant form 
of the αLG4-51443-1820 as shown in figure 21, in order to be able to utilize the 
fragment in our cell culture system and thereby mimicking a potential downstream 
effect of HTRA1´s action on the hMSCs. 
 
                                               
Figure 21: Purified baculovirus generated recombinant αLG4-51443-1820 
fragment (3 µg) separated on a SDS-PAGE gel and visualized by Coomassie 
blue staining. 
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After its successful production and purification, the fragment was tested for its 
effects on oil droplet formation in hMSCs undergoing adipogenesis (Fig. 22). We 
observed a significant and dose dependent decrease in oil droplet formation in 
differentiating hMSCs after 18 days of treatment with αLG4-5 at concentrations 
ranging from 0.25 to 1 µg/ml, thereby confirming the HTRA1-generated laminin-α4 
fragments could indeed influence hMSC adipogenesis. 
 
 
                    
Figure 22: Quantification of Oil Red O staining of hMSCs treated with varying 
concentrations of recombinant αLG4-5 at day 18 post adipogenic induction. 
*P < 0.001 as compared to untreated. 
 
 
 
As we could already show that the effects on oil droplet formation of hMSCs were 
due to HTRA1´s ability to induce MMP secretion [177], we subsequently analyzed 
the effects of the αLG4-5 treatment on MMP protein secretion (Fig. 23). However, 
no significant increases in MMP-3 protein production were observed. 
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Figure 23: Effect of recombinant αLG4-5 on MMP-3 protein secretion in 
adipogenic hMSCs at day 14. 
 
 
By contrast, MMP-13 protein secretion was significantly downregulated in cells 
treated with αLG4-5 at all concentrations tested (Fig. 24). 
                                     
Figure 24: Effect of recombinant αLG4-5 on MMP-13 protein secretion in 
adipogenic hMSCs at day 14. 
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Furthermore, when silencing laminin-α4 expression in hMSCs using siRNA, we 
were able to significantly enhance oil droplet formation in both untreated and 
HTRA1-treated adipogenic hMSCs (Fig. 25), while the effect of HTRA1 on oil 
droplet formation was still maintained, but to a lesser degree. Thus, HTRA1´s 
ability to inhibit oil droplet formation in hMSCs undergoing adipogenesis may 
partially be reliant on the actions of reactive laminin-α4 fragments. However, this 
appears to be independent of MMP production by the cells. 
 
                                   
Figure 25: Quantification of Oil Red O staining of hMSCs treated with or 
without HTRA1 and knockdown of laminin-α4 with two different oligos at day 
18 post adipogenic induction. *P < 0.001 as compared to untreated. 
 
Preparation of recombinant αLG4-51443-1820. Overexpression of human his-
tagged αLG4-51443-1820 was performed in SF21 insect cells using the pBacPAK8 
Vector system (Clontech Laboratories, Saint-Germain-en-Laye, France) according 
to the manufacturer’s protocol. αLG4-51443-1820 was purified by affinity 
chromatography using HisTrap FF Crude columns (GE Healthcare, Glattbrug, 
Switzerland) followed by size exclusion chromatography. Purified protein was 
subsequently concentrated using Amicon Ultra columns (10kDa size exclusion, 
Millipore) prior to use.  
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5 General discussion and perspectives 
The ubiquitously expressed trypsin-like serine protease HTRA1 is undoubtedly 
involved in the regulation of a large number of intracellular and extracellular 
processes [140, 150, 166, 177, 180-182]. As many of these processes involve 
cross talk between important signaling pathways (e.g. TGF-β signaling), it is likely 
that HTRA1 levels must be carefully regulated to allow for the normal functioning 
of healthy tissue. It is therefore not surprising that HTRA1 can be regarded as 
having either a beneficial or detrimental role in disease [109]. The work described 
in this thesis primarily focuses on the role of HTRA1 in the regulation of hMSC 
adipogenesis. The basis for this study comes from the observation that HTRA1 
acts as a positive mediator of hMSC osteogenesis, thus implicating it in bone 
formation and repair. Interestingly, the differentiation of hMSCs towards 
osteogenesis and adipogenesis is often regulated in a reciprocal manner [175]. 
Furthermore, the bones of patients with osteoporosis are characterized by having 
low bone mass in combination with significantly increased levels of fat marrow 
[183-185]. This leads to the assumption that a dysfunctional bone marrow tissue 
favors hMSC adipogenesis over the desired osteogenesis. Indeed, both animal 
and human studies have repeatedly demonstrated a significant impairment in the 
capacity of resident bone hMSCs from osteoporotic subjects to undergo 
osteogenesis, whilst adipogenic capabilities remain intact and in some instances 
even elevated [186]. In the presented work, we demonstrate that HTRA1 has a 
strong effect on hMSC lineage commitment, where it acts to suppress 
adipogenesis [177], whilst promoting osteogenesis [165]. Hence, it could be 
considered as a potential gatekeeper of multi lineage commitment in hMSCs. 
However, the question as to which pathways are affected in the facilitation or 
suppression of either of the two lineage commitments remains open. Still, with 
regards to hMSC adipogenesis, some important insights are offered by the 
findings within this thesis, highlighting MAP kinase-dependent upregulation of 
MMPs as being a possible means through which HTRA1 mediates its suppressive 
effects [177]. 
The influence of HTRA1 on ECM turnover has been well described and has been 
linked to various diseases in which ECM breakdown is a central pathological 
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feature [107, 129, 146, 148, 156]. This breakdown of tissue material is realized by 
an upregulation of MMPs which, in turn, is most likely mediated through the 
actions of reactive fibronectin fragments (Fnf) species, as shown by our own lab in 
the context of HTRA1´s involvement in joint and IVD degeneration [107, 129]. 
However, in adipose tissue homeostasis and development, ECM remodeling and 
reorganization by MMPs is a well-known requirement for adipose-tissue integrity 
and stem cell adipogenesis [187, 188]. The dysregulation of MMP production may 
therefore be an underlying cause for several adipose tissue-related diseases and 
may define adipocyte health in general. Our own findings support this hypothesis, 
as an increased production of MMP-1, -3 and -13 by adipogenic hMSCs upon 
stimulation with HTRA1 was found to lead to a loss of several ECM components 
and ultimately to a decrease in lipid accrual [177]. Thus, HTRA1 is suggested to 
have a detrimental role in hMSC adipogenesis via the upregulation of MMPs. 
Surprisingly, these effects were found to be independent of Fnfs, while evidence 
was found to suggest that MMP-13 itself is responsible for the generation of these 
fragments in response to HTRA1. We therefore speculate that alternative 
mechanisms must exist through which HTRA1´s ability to regulate MMP 
production is mediated by hMSCs. 
We were able to gain some insights into the detailed mechanism of how HTRA1´s 
actions are mediated by manipulating its trypsin-like serine protease domain, as 
well as its protein-binding PDZ domain. Conclusively, both domains are necessary 
in order to allow for its inhibitory influence on hMSC adipogenesis via the 
production of MMPs, the decrease in type IV collagen and laminin, as well as the 
decrease in lipid uptake. Importantly, it was found that HTRA1 could directly 
interact with surface bound heparan sulfate (HS) via its PDZ domain. This 
sequestration of HTRA1 to the cell surface could therefore potentially allow for it to 
closely interact with HS-containing glycoproteins, i.e. potential substrates. Indeed, 
evidence is given by the fact that we were able to detect increased levels of 
soluble syndecan-4 as a result of adipogenic hMSCs being exposed to structurally 
intact HTRA1. Since syndecans are known to be important regulators of lipid 
uptake in differentiating adipocytes [189, 190], the release of syndecan-4 from the 
cell surface may explain the observed inhibition of lipid accrual in adipogenic 
hMSCs treated with HTRA1. In addition to syndecans, other glycoproteins exist 
within the ECM of adipocytes which are potential substrates of HTRA1. One 
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example is nidogen, which was successfully shown to be a substrate of HTRA1 
[146] and which represents an important stabilizing element of the adipocyte basal 
lamina through its binding to type IV collagen and laminin [191]. Thus, nidogen 
cleavage by HTRA1 and the subsequent stimulatory effects of the fragments may 
therefore be an alternative route through which HTRA1 mediates its inhibitory 
effects on adipocyte maturation and development. 
Additionally, HTRA1´s ability to both induce MMP production and inhibit hMSC 
adipogenesis was considered as being dependent on JNK activity and, to a lesser 
extent, ERK. The interpretation of the involvement of p38 was hampered by the 
fact that the inhibition of p38 activation resulted in a decreased oil droplet 
formation in adipogenic hMSCs throughout all treatment conditions. The regulation 
of MMP expression is primarily through MAP kinase activation [192] and several 
studies have been able to demonstrate an ERK and JNK involvement in the 
suppression of hMSC adipogenesis [193-195]. Although unable to ascertain its 
cause, we were able to identify MAP kinase activation as a central factor in 
mediating the effects of HTRA1 during hMSC adipogenesis. Furthermore, both the 
proteolytic activity and PDZ domain are required for efficient MAP kinase 
activation. Hence, both its binding and its ability to degrade specific substrates are 
required for HTRA1 to influence MAP kinase activation in hMSCs.  
Syndecan-4 shedding may represent one potential means by which HTRA1 could 
act on MAP kinase activation, whereby the disruption of the syndecan-4 to MAP 
kinase signaling cascade contributes to an increased JNK activation [196]. 
Importantly, both MAP kinases and MMPs are known to be central factors in the 
pathophysiology of adipose tissue, even extending to the development of insulin 
resistance in obese mice and humans [197-199]. The severity of insulin resistance 
among obese patients clearly involves adipocyte integrity [200]. Thus, factors 
negatively influencing adipogenesis of hMSCs and adipocyte function are likely to 
contribute to and possibly instigate insulin resistance. Therefore, inappropriately 
high levels of HTRA1 in the adipose tissue of obese individuals can be interpreted 
as being an indicator of deficiencies and malfunctions in the development of 
adipocytes within adipose tissue. In line with this, we were able to detect HTRA1 in 
the visceral fat from obese patients, with levels being greatest at sites of cellular 
infiltration and crown-like structures. Furthermore, MMP-13 was also localized to 
the same regions of the fat tissue as HTRA1, thus re-enforcing the concept of 
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there being a close working relationship between these two proteases. We 
furthermore suggest macrophages as representing a potential cellular source for 
HTRA1 in the fat tissue, as they are considered to be the predominant cell type in 
crown-like structures [37, 201] and are known to be potent inducers of MMPs in 
adipocytes [202]. 
Undoubtedly, this thesis only addresses a small part of a wider story, and to 
understand exactly how HTRA1’s ability to manipulate the ECM results in a 
dysregulation of hMSC differentiation will require more detailed investigations. For 
instance, the influence of HTRA1 on TGF-β has been well characterized in other 
cell systems [154, 166], where an upregulation of TGF signaling can be observed 
due to the lack of attenuation of TGF-β signaling events by HTRA1. Since TGF-β 
signaling is known to have a central role in the regulation of stem cell 
differentiation [203, 204], it appears logical that the effect of HTRA1 on adipogenic 
hMSCs is also partially driven via the TGF-β pathway. Another important aspect is 
the maturation and activity state of many of the factors involved. Here, the actual 
enzymatic activity of HTRA1 as well as that of the MMPs is of great importance, as 
they are known to exist in activate and inactive states both inside and outside of 
the cell [205, 206]. We cannot rule out the fact that HTRA1´s effects are, to a 
certain extent, also occurring intracellularly. More importantly however, the impact 
of protease inhibitors (e.g. serpins, TIMPs) could also be of significant importance. 
Certainly, gene expression studies, as well as ex vivo activity assays of certain 
enzymes, may be able to shed some light on the potential players regulating 
HTRA1’s impact on the ECM, as well as on the cells themselves. Also, other parts 
of adipocyte maturation were not addressed within this study. One example is 
lipolysis, which ensures a constant release of free fatty acids from mature 
adipocytes [207, 208]. Dependent on whether or not the net inflow exceeds the 
outflow, the cells accumulate or reduce their overall oil droplet content (c.f. chapter 
1.2.1.1). Thus, an increase in lipolysis is a scenario, which could contribute to the 
effects of HTRA1 on hMSCs undergoing adipogenesis. By analysing protein 
amounts of the hormone-sensitive lipase (HSL) by Western blot, this part of the 
fatty acid homeostasis could be addressed rather easily. 
As previously mentioned, ECM fragments other than Fnfs might potentially be 
involved in mediating the effects of HTRA1 on hMSC adipogenesis. During the 
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course of this study, we confirmed laminin-α4 as being an HTRA1 substrate, 
identifying several fragments within the supernatants of HTRA1 treated hMSCs 
(c.f. section 4, figures 18 – 21). In order to further investigate their potential role in 
regulating adipogenesis, we treated cells with the recombinant laminin-α4 
fragment produced by HTRA1, called αLG4-5. We consistently found that αLG4-5 
was capable of inhibiting oil droplet formation in the adipogenic hMSCs (section 4, 
figure 22). However, this process appeared to be independent of MMPs, based on 
a lack of MMP-3 upregulation, and even a significant decrease in MMP-13 
production (section 4, figure 23 + 24). Therefore, it is possible that HTRA1’s 
inhibitory actions towards hMSC lipid accrual may also involve the actions of 
reactive laminin-α4 fragments, independently of MMP activity. However, we also 
speculated that MMPs induced by HTRA1 could themselves generate the reactive 
αLG4-5 fragments, thereby explaining the lack of effects seen with NNGH in 
preventing loss of lipid droplet accumulation in αLG4-5-treated cells. Thus, the 
effects seen by the αLG4-5 fragment on adipogenesis could potentially be 
explained by the diverse implications of the fragments on hMSCs undergoing 
adipogenesis. As proposed by Yamashita et al [179], the αLG4-5 fragment may 
modulate FGF-2 signaling directly by binding to syndecans via their 
heparin-binding region, thereby blocking the actions of FGF resulting in the 
suppression of adipogenesis [209]. 
Thus, HTRA1 may represent a master regulator between adipogenesis and 
osteogenesis, determining, the cellular fate of hMSCs. If indeed the case, this may 
have far reaching implications for the maintenance of tissue where stem cell 
commitment plays an important role. One such example is in white adipose tissue 
(WAT), where inhibition of hMSC adipogenesis by exposure to HTRA1 may be 
considered detrimental with regards to the maintenance of adipocyte function [210, 
211]. Furthermore, increased levels of HTRA1 within adipose tissue may even 
represent a biomarker for insulin-resistance and possibly an additional diagnostic 
factor for type 2 diabetes. Moreover, fully functional adipocytes within the WAT are 
a prerequisite for appropriate insulin sensitivity of the adipose tissue and thereby 
ultimately have implications for the whole body. A cell with a dysfunctional ECM 
environment caused by different proteases, may contribute to the loss of insulin 
sensitivity of the tissue itself. This may be caused by an increase of fatty acids in 
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the circulation of the body due to a relative low net intake of fatty acids into the fat 
tissue, thereby disturbing the insulin response pathways [200, 212]. In addition, 
the cell’s ability to affect a proper insulin response may also be influenced by 
alterations in cell surface receptor availability (e.g. GLUT-4) [213] due to 
pathological levels of HTRA1. This could be addressed by employing a high fat 
diet model using Htra1-/- knockout mouse model, where the ensuing obese 
phenotype may be significantly altered as compared to wild type mice, resulting in 
a slower onset of diabetes type II in these mice. However, this was considered 
outside the realms of this particular study. It is therefore envisaged that future 
studies will be required in order to fill the gaps in our knowledge regarding the 
impact of HTRA1 on adipogenesis in vivo. Furthermore, a more detailed 
understanding of the intracellular responses initiated by the exposure of the 
hMSCs to HTRA1-generated ECM fragments, in particular laminin-α4, is required 
in order to identify new possible therapeutic targets. Moreover, it would be 
interesting to translate the findings from the current study on adipogenesis to the 
osteogenesis system. Here the reciprocally regulated effects could be studied 
further, thereby allowing for additional insights into the transition and differentiation 
between osteogenesis and adipogenesis in more detail. Furthermore, details 
about time-dependent changes of certain intracellular pathways over the whole 
time period of the differentiation and HTRA1 treatment procedure would help to 
further identify potential signaling cascades involved in mediating HTRA1’s effects. 
Certainly, arrays targeting the secretome of cells undergoing differentiation and 
the ECM composition would help tremendously in providing additional information 
with regards to the changes occurring during osteo- and adipogenesis in the 
presence and absence of HTRA1.  
In conclusion, our findings highlight HTRA1 as being a central negative regulator 
of hMSC adipogenesis. The relevance of this is made evident by the fact that the 
adipose tissue plays an important role in many processes of the human body, 
being involved in regulating energy homeostasis of the skeletal musculature and 
other tissues. Importantly, the differential effect of HTRA1 on hMSC adipogenesis 
and osteogenesis offers novel insights into its potential impact on other diseases 
such a age-related bone loss, where HTRA1´s capacity to inhibit adipogenesis and 
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to promote osteogenesis would be considered beneficial  in the maintenance of 
normal bone quality [212, 214]. 
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